Susquehanna International Group’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.2M | Buy |
3,205,339
+1,155,728
| +56% | +$5.85M | ﹤0.01% | 498 |
|
|
2025
Q1 | $10.8M | Buy |
2,049,611
+382,622
| +23% | +$2.02M | ﹤0.01% | 607 |
|
|
2024
Q4 | $11.3M | Buy |
1,666,989
+597,390
| +56% | +$4.04M | ﹤0.01% | 666 |
|
|
2024
Q3 | $7.05M | Sell |
1,069,599
-297,031
| -22% | -$1.96M | ﹤0.01% | 823 |
|
|
2024
Q2 | $10.2M | Buy |
1,366,630
+532,758
| +64% | +$4M | ﹤0.01% | 667 |
|
|
2024
Q1 | $8.31M | Buy |
833,872
+469,674
| +129% | +$4.68M | ﹤0.01% | 751 |
|
|
2023
Q4 | $3.59M | Buy |
364,198
+56,365
| +18% | +$556K | ﹤0.01% | 1403 |
|
|
2023
Q3 | $2.35M | Buy |
307,833
+210,048
| +215% | +$1.61M | ﹤0.01% | 1701 |
|
|
2023
Q2 | $730K | Sell |
97,785
-106,618
| -52% | -$796K | ﹤0.01% | 3129 |
|
|
2023
Q1 | $1.36M | Buy |
204,403
+142,403
| +230% | +$950K | ﹤0.01% | 2452 |
|
|
2022
Q4 | $478K | Sell |
62,000
-24,055
| -28% | -$185K | ﹤0.01% | 3280 |
|
|
2022
Q3 | $916K | Buy |
86,055
+58,570
| +213% | +$623K | ﹤0.01% | 2657 |
|
|
2022
Q2 | $224K | Sell |
27,485
-25,342
| -48% | -$207K | ﹤0.01% | 4410 |
|
|
2022
Q1 | $378K | Sell |
52,827
-152,899
| -74% | -$1.09M | ﹤0.01% | 4067 |
|
|
2021
Q4 | $3.52M | Buy |
205,726
+88,466
| +75% | +$1.52M | ﹤0.01% | 1465 |
|
|
2021
Q3 | $2.7M | Buy |
117,260
+66,614
| +132% | +$1.53M | ﹤0.01% | 1664 |
|
|
2021
Q2 | $1.85M | Buy |
+50,646
| New | +$1.85M | ﹤0.01% | 2164 |
|